VIDEO: Deepak L. Bhatt, MD, MPH, discusses gene editing, ORBITA-2, artificial intelligence
Click Here to Manage Email Alerts
PHILADELPHIA — In this video exclusive, Deepak L. Bhatt, MD, MPH, provides his perspective on research presented at the American Heart Association Scientific Sessions.
Bhatt discusses the first-in-human, phase 1b heart-1 trial that assessed safety and efficacy of gene editing with VERVE-101 (Verve Therapeutics), a novel CRISPR base-editing medicine, for the treatment of heterozygous familial hypercholesterolemia.
“What they found was a significant reduction in PCSK9 levels and, importantly, a 50% reduction in LDL levels. ... To see this in humans, I think is an incredible milestone in medical history,” Bhatt said.
Bhatt also provides highlights from the ORBITA-2 trial, which found that PCI improved angina symptoms at 12 weeks compared with a sham procedure in patients with stable angina and evidence of ischemia.
“I hope this resolves some controversy, that in part was started by ORBITA-1, about whether PCI really works or not,” Bhatt said.
Bhatt also announced from the podium at AHA 2023 the TRANSFORM trial (sponsored by Cleerly), which will enroll and randomize 7,500 patients with prediabetes, type 2 diabetes or metabolic syndrome and no symptoms of CVD to usual care or a personalized strategy of coronary CT angiography and an artificial intelligence-enabled investigational plaque staging system to inform medical decisions.
“The idea is to see whether staging coronary plaque actually improves outcomes,” Bhatt said.
Watch the video for take-home messages from Bhatt, who is director of Mount Sinai Heart, the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai and a member of the Healio | Cardiology Today Editorial Board.
Collapse
Click Here to Manage Email Alerts